CTLA4 and neoplasm: CD8+ T cell mediated anti-tumor immunity of promising cancer immunotherapy, including DC cancer vaccines, adaptability of reactive T cell tumor cell metastasis (ACT) and free of disease checkpoint blockade, such as resistance to PD-1, PD-L1, and resisting CTLA-4 (26), PD-1 therapy is associated with the abundance of CD8+ T cells that support tumor invasion, tumor mutation load, and interferon signaling (30).